Related Experiment Video
Updated: Jan 22, 2026
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Azathioprine dosing and metabolite measurement in pediatric inflammatory bowel disease: does one size fit all?
Rebecca Walker1, Jochen Kammermeier1, Rakesh Vora1
1Department of Paediatric Gastroenterology, Evelina London Children's Hospital, London, UK.
Insights
Optimizing azathioprine dosing in pediatric inflammatory bowel disease (IBD) is crucial. Measuring thiopurine metabolites and IBD activity early helps tailor treatment and prevent adverse effects.
Area of Science:
- Pediatric Gastroenterology
- Pharmacogenomics
- Immunosuppressive Therapy
Background:
- Azathioprine is a key maintenance therapy for pediatric inflammatory bowel disease (IBD).
- Monitoring thiopurine metabolites, 6-thioguanine (6-TGN) and 6-methyl-mercaptopurine (6-MMP), is vital for optimizing efficacy and minimizing toxicity.
- A proactive approach integrating metabolite levels with disease activity assessments is proposed.
Purpose of the Study:
- To evaluate a proactive strategy for azathioprine dosing in pediatric IBD.
- To correlate thiopurine metabolite levels with IBD activity indices.
- To assess the impact of this approach on treatment adjustments and patient outcomes.
Main Methods:
- Retrospective analysis of 40 children with IBD treated with azathioprine.
- Evaluation of azathioprine dosage, IBD activity scores, and thiopurine metabolite levels (6-TGN, 6-MMP).
- Assessment of additional treatments and effects on blood counts.
Main Results:
- The study included 40 children (mean age 12.2 years) with IBD (Crohn's disease, ulcerative colitis).
- Mean 6-TGN was 280 pmol/8x10^8 RBC, mean 6-MMP was 1022 pmol/8x10^8 RBC, and mean IBD activity index was 6.5.
- Azathioprine dose adjustments were needed in 12 children, while 28 did not require changes.
Conclusions:
- Early measurement of thiopurine metabolites combined with clinical assessment optimizes azathioprine dosing in pediatric IBD.
- This proactive strategy aids in reducing serious adverse effects.
- Personalized medicine approaches are essential for managing IBD in children.
Background:
Azathioprine is widely used for the maintenance of remission in children with inflammatory bowel disease (IBD). Measuring thiopurine metabolites 6-thioguanine (6-TGN) and 6-methyl-mercaptopurine (6-MMP) can aid in optimizing treatment and preventing toxicity. We report a proactive approach combining early metabolite measurements with IBD activity index to achieve optimal azathioprine dosing.
Methods:
The reporting of azathioprine dosing, IBD activity indexes and thiopurine metabolites was evaluated retrospectively in 40 children with IBD. Additional treatments and the effect of azathioprine on blood counts were also examined.
Results:
Forty children (40% female) with IBD (26 Crohn's disease, 12 ulcerative colitis, and 2 unclassified IBD), mean age 12.2±3.4 years, were included in the study. The mean azathioprine dose was 1.3±0.4 mg/kg; mean 6-TGN level was 280±151 pmol/8 × 108 red blood cells (RBC) and mean 6-MMP level 1022±1007 pmol/8 × 108 RBC. Disease activity index (Crohn's and ulcerative colitis, pediatric specific) at the time of metabolite measurement was 6.5±8. Twenty-eight children did not require azathioprine dose adjustment, while it was increased in 12. Data from children with azathioprine monotherapy were analyzed separately and the results were similar.
Conclusion:
Timely measurement of thiopurine metabolites and clinical assessment can provide a powerful tool to optimize azathioprine dosing and reduce serious adverse effects in children with IBD.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Dose Size and Dosing Frequency: Determination Methods